Bronchiectasis and NTM 360 Published Manuscripts

Aksamit TR, Locantore N, Addrizzo-Harris D, et al. Five-Year Outcomes Among U.S. Bronchiectasis and Nontuberculous Mycobacterial Registry Patients. Am J Respir Crit Care Med. Epub 2024 Apr 26; DOI: 10.1164/rccm.202307-1165OC.

Basavaraj A, Brunton AE, Choate R, Nebulized hypertonic saline and positive expiratory pressure device use in patients with bronchiectasis: Analysis from the United States Bronchiectasis and NTM Research Registry. Respir Res. Epub 24 April 2024. DOI:

Basavaraj A, Choate R, Becker C, Severity of bronchiectasis predicts use of and adherence to high frequency chest wall oscillation therapy - Analysis from the United States Bronchiectasis and NTM Research Registry. Respir Med. 2024 Mar; 223:107555. DOI:

Karamooz E, Brixey A, Rydzak C Prevalence of pulmonary artery dilation in non-cystic fibrosis bronchiectasis: A CT analysis from a cohort of the US Bronchiectasis and Nontuberculous Mycobacteria Research Registry. J Thorac Dis. Epub 27 Feb 2024. DOI:

Drysdale M, Choate R, Brunton AE, et al. Nontuberculous mycobacterial (NTM) infections in bronchiectasis patients: A retrospective US registry cohort study. Pulm Pharmacol Ther. 2023 Dec:83:102260. Epub 2023 Sep 21.

McShane PJ, Choate R, Johnson M, et al. Bronchiectasis and NTM Research Registry Investigators. Racial and ethnic differences in patients enrolled in the national bronchiectasis and nontuberculous mycobacteria research registry. Respir Med. 2023 Apr; 209:107167. DOI:

Ku JH, Henkle E, Aksamit TR, et al. Treatment of Nontuberculous Mycobacterial (NTM) Pulmonary Infection in the US Bronchiectasis and NTM Registry: Treatment Patterns, Adverse Events, and Adherence to American Thoracic Society/Infectious Disease Society of America Treatment Guidelines. Clin Infect Dis. 2023 Jan 13;76(2):338-341. DOI:

Henkle E, Brunton AE, Aksamit TR, Winthrop KL. Isolation of Pseudomonas aeruginosa after nontuberculous mycobacteria. IJTLD. 2022; 26(5): 460-462. DOI:

Metersky ML, Choate R, Aksamit TR, Conrad D, Lapinel N, Maselli D, McShane PJ. Stenotrophomonas maltophilia in patients with bronchiectasis: An analysis of the US bronchiectasis and NTM Research Registry. Respir Med. 2022; 193: 106746. DOI:

McShane PJ, Philley JV, Prieto DA, Aksamit TR. Global attitudes of health care providers about aerosolized airway clearance therapy in bronchiectasis patients during the coronavirus disease 2019 pandemic. Chronic Obstr Pulm Dis. 2021; 8(3): 319-325. doi:

Metersky ML, Choate R; Bronchiectasis and NTM Research Registry Investigators. The Association of Long-term Macrolide Therapy and Nontuberculous Mycobacterial Culture Positivity in Patients With Bronchiectasis. Chest. 2021 Aug;160(2):466-469. Epub 2021 Feb 20.

Pravosud V, Mannino DM, Prieto D, et al. Symptom burden and medication use among patients with nontuberculous mycobacterial lung disease. Chronic Obstr Pulm Dis. 2021; 8(2): 243-254. doi:

Choate R, Aksamit TR, Manino D, et el. Pseudomonas aeruginosa associated with severity of non-cystic fibrosis bronchiectasis measured by the modified bronchiectasis severity score (BSI) and the FACED: The US bronchiectasis and NTM Research Registry (BRR) study. Respir Med. 2021; 177. Epub 2020 Dec 23. DOI:

Basavaraj A, Choate R, Addrizzo-Harris D, et al. Airway Clearance Techniques in Bronchiectasis: Analysis From the United States Bronchiectasis and Non-TB Mycobacteria Research Registry. CHEST. 2020; 158(4): 1376-1384. DOI:

Despotes KA, Choate R, Addrizzo-Harris D, et al. Nutrition and Markers of Disease Severity in Patients With Bronchiectasis. Chronic Obstr Pulm Dis. 2020; 7(4): 390-403. DOI:

Eden E, Choate R, Barker A, et al. The clinical features of bronchiectasis associated with alpha-1 antitrypsin deficiency, common variable immunodeficiency and primary ciliary dyskinesia--results from the U.S. Bronchiectasis Research Registry. Chronic Obstr Pulm Dis. 2019; 6(2): 145-153. DOI: HTTP://DOI.ORG/10.15326/JCOPDF.6.2.2018.0156

Henkle E, Aksamit TR, Daley CL, et al. US Patient-Centered Research Priorities and Roadmap for Bronchiectasis. Chest. 2018; 154 (5), 1016-1023. DOI: HTTPS://DOI.ORG/10.1016/J.CHEST.2018.06.032

Metersky ML, Aksamit TR, Barker A, et al. The prevalence and significance of Staphylococcus aureus in patients with non–cystic fibrosis bronchiectasis. Ann Am Thorac Soc. 2018; 15:365–370. DOI: HTTPS://DOI.ORG/10.1513/ANNALSATS.201706-426OC

Henkle E, Chan B, Curtis JR, et al. Characteristics and Health-care Utilization History of Patients With Bronchiectasis in US Medicare Enrollees With Prescription Drug Plans, 2006 to 2014. Chest. 2018; 154(6): 1272-1273. DOI:

Henkle E, Curtis JR, Chen L, et al. Comparative risks of chronic inhaled corticosteroids and macrolides for bronchiectasis. Eur Resp J. 2018; 54(1): 1801896. DOI:

Henkle E, Aksamit TR, Barker AF, et al. Pharmacotherapy for Non-Cystic Fibrosis Bronchiectasis Results From an NTM Info & Research Patient Survey and the Bronchiectasis and NTM Research Registry. Chest. 2017; 152 (6), 1120-1127. DOI: HTTPS://DOI.ORG/10.1016/J.CHEST.2017.04.167

Ruffner MA, Aksamit TR, Thomashow B, et al. Frequency of untreated hypogammaglobulinemia in bronchiectasis. Ann Allergy Asthma Immunol. 2017; 119 (1), 83-85. DOI: HTTPS://DOI.ORG/10.1016/J.ANAI.2017.04.020

Aksamit TR, O’Donnell AE, Barker, A, et al. Adult Patients with Bronchiectasis A First Look at the US Bronchiectasis Research Registry. Chest. 2017; 151 (5), 982-992. DOI: HTTPS://DOI.ORG/10.1016/J.CHEST.2016.10.055